Quick Answer
Chemomab Therapeutics Ltd. reported Diluted EPS of $0.02 per share for fiscal year 2025.
Chemomab Therapeutics Ltd. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.02 | -53.8% |
| 2024 | $0.04 | -62.1% |
| 2023 | $0.10 | -14.9% |
| 2022 | $0.12 | +101.7% |
| 2021 | $0.06 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $0.04 | +81.8% | +14.3% |
| September 30, 2022 | $0.04 | +169.2% | +29.6% |
| June 30, 2022 | $0.03 | +107.7% | +22.7% |
| March 31, 2022 | $0.02 | — | +69.2% |
| September 30, 2021 | $0.01 | — | +0.0% |
| June 30, 2021 | $0.01 | — | — |
- Chemomab Therapeutics Ltd. showed a decrease of -53.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Chemomab Therapeutics Ltd.’s diluted eps has declined by 70.0% (from $0.06 per share to $0.02 per share).
- The most recent figure is from Chemomab Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: